



PRIVATE FUNDING OPPORTUNITIES: MAY 5, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

1. Familial RUNX1 Grant Program: Familial RUNX1 Research Grant, Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

Alex's Lemonade Stand Foundation (ALSF) is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloblastic leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML. ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around familial RUNX1 disorders.

Purpose of the grant is to fund research that will develop strategies leading to the development of therapies for the prevention of the transition from pre-leukemia to leukemia for patients with the familial RUNX1 disorder. Projects should focus on familial RUNX1 disorder rather than acquired RUNX1 mutations seen during the evolution of AML.

Research Directions of Interest:

- Studies that develop our understanding of the biological basis for disease progression in individuals carrying familial RUNX1 mutations.
- Studies to develop potential therapies to limit disease progression from individuals with the familial RUNX1 deficiency.
- Development of in vitro and in vivo model systems (including but not limited to human cell, mouse or zebrafish) that: increase our understanding of disease pathogenesis, test mechanistic hypotheses, or that provide a suitable evaluation platform for the discovery of potential therapies.



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.

The grant is designed as seed funding for researchers with a novel scientific approach to investigating hereditary or germline RUNX1 disorder. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator's prior research, but for which a strong case can be made for the potential impact on familial RUNX1 disorder.

Award Amount: \$250,000 paid over 2 years

Indirect Costs: None

LOI Deadline: Jun 1, 2017

Website: <http://www.alexlemonade.org/grants/runx1>

2. Psychosocial Grant Program: Psychosocial Family Impact Grants, Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

ALSF is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Psychosocial Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact.

The Psychosocial: Family Impact Grants will support studies by established investigators that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact.

Award Amount: \$300,000 paid over 3 years

Indirect Costs: None

LOI Deadline: Jun 9, 2017

Website: <https://www.alexlemonade.org/grants/program-areas/quality-life-and-care#program-141>

3. Psychosocial Grant Program: Psychosocial Launch Grants, Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

ALSF is committed to addressing the psychosocial and behavioral health outcomes for children diagnosed with cancer and their families. Psychosocial Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact.

The Psychosocial: Launch Grants will support studies by early career researchers that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer.

Demonstration of outstanding mentorship and a career plan that shows commitment to pediatric cancer investigation are important components of a successful application.

Award Amount: \$100,000 paid over 2 years

Indirect Costs: None

LOI Deadline: Jun 9, 2017

Website: <http://www.alex slemonade.org/grants/program-areas/quality-life-and-care#program-141>

4. Research and Training Scholarships - ABOG/AAOGF and Pregnancy (SMFM) Foundation/AAOGF, American Gynecological and Obstetrical Society (AGOS)/American Association of Obstetricians and Gynecologists Foundation (AAOGF)

The AAOGF and the Foundations of ABOG and SMFM seek to identify future academic physician leaders in the field of Obstetrics and Gynecology and to stimulate their scholarly development, through the support of advanced scientific training. The Scholarship Award is to be used in an academic Department of Obstetrics and Gynecology in the United States or Canada to provide research training and experience for a candidate of proven ability who exhibits significant talent, original thought and evidence of dedication to an academic career. Research training may be either laboratory-based or clinical, and focus on basic or translational research, disease pathogenesis, diagnostics, interventions or epidemiology.

Applications for the AAOGF/Pregnancy (SMFM) Foundation award should focus on an area of relevance to the discipline of Maternal-Fetal Medicine and Obstetrics.

At least 75% of the candidate's efforts should be spent in research training and conduct of research, which may occur in facilities either within or outside of the sponsoring Department of Obstetrics and Gynecology. Collaborative efforts with other departments e.g., Pharmacology, Molecular and Cell Biology, Genetics, Immunology, Biochemistry, or Epidemiology would be a desirable part of the program.

Award Amount: \$120,000 for 1 year

Indirect Costs: None

Application Deadline: Jul 1, 2017

Website: <http://www.aaogf.org/scholarship.asp>

5. Grant for Hire Program - PHA Barst Fund Grants, American Thoracic Society (ATS)/ American Thoracic Society (ATS) Foundation New

The focus of the grants is to support research projects that are in the early and developmental stages and targeted at the basic sciences, genetics, pathophysiology, epidemiology, diagnosis, or treatment of pediatric Pulmonary Hypertension (PH). The novel biological, behavioral or scientific ideas, combined with experienced mentor collaboration, are expected to significantly

advance the grantee's knowledge, and ultimately, the field of pediatric PH. The Pulmonary Hypertension Association (PHA) contracted with the American Thoracic Society for administrative services for this program.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

LOI Deadline: Jun 6, 2017

Website: <http://www.thoracic.org/professionals/research/research-program-portfolio/grant-for-hire-loi-2017.php>

6. Research Grant, Histiocytosis Association

At the very heart of the association is the steadfast commitment to finding a cure for histiocytic disorders. The Research Program was established in 1990 by the Association's Board of Trustees with the objective of identifying and funding the most important and promising research initiatives - those that will lead to more effective treatments and, ultimately, a cure.

The Program provides funding for two types of scientific research - basic and clinical. Basic scientific research focuses on understanding the function of cells and the disease process, and is generally conducted in a laboratory under controlled settings. Clinical scientific research utilizes the knowledge generated through basic research and applies it directly to the treatment of patients through clinical trials. These two forms of research complement one another, and both are necessary in the quest for better treatments and, ultimately, a cure for histiocytic disorders.

Proposals for scientific research are accepted for studies into the causes, mechanisms, and improved means of treatment for histiocytic disorders. Proposals are evaluated on the basis of science, feasibility, and relevance. All proposals are expected to address one or more of the histiocytic disorders; below are areas of particular interest; however, all relevant areas of interest are considered.

- Mechanisms of disease pathogenesis
- Biology (maturation, migration and immune function) of dendritic cells, macrophages and/or lymphocytes in disease pathogenesis
- Derangements of cytokine production or function
- CNS pathology
- Neuropsychiatric consequences
- Studies of rare forms -- Juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman disease
- Studies of histiocytic disorders in adults
- Discovery of new disease markers
- Overall support of clinical trials

Award Amount: \$50,000 for 1 year
Indirect Costs: None
Proposal Deadline: Jul 1, 2017
Website: <http://www.histio.org/RFRP>

7. SWOG Early Exploration and Development (SEED) Fund, The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials.

Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain extramural funding based on studies done during the tenure of the support of this grant.

The Hope Foundation SEED Fund encourages well-defined projects which have strong potential to direct future SWOG research and which realistically can be completed in 1-2 years. Because the research proposal is of limited scope a SEED grant application will not contain extensive detail or rise to the level of discussion found in a SWOG/Hope Impact award proposal. Accordingly, reviewers will evaluate the direct correlation to future SWOG research potential, emphasizing conceptual framework and general approach to the problem, placing less emphasis on methodological details and certain indicators traditionally used in evaluating the scientific merit of Impact applications including supportive preliminary data. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.

Award Amount: \$50,000 for 1-2 years
Indirect Costs: 25%
Application Deadline: Jul 1, 2017
Website: <https://thehopefoundation.org/research-funding/juried-programs/swog-early-exploration-development-seed-fund/>

8. Rising Star Research Awards, One Mind Institute (formerly IMHRO)

Given the challenges of understanding and finding therapies for brain disorders, these awards aim to encourage the community of neuroscience researchers to direct their efforts toward

collaborative basic and translational science, while supporting the research of emerging leaders in the field.

In 2017, One Mind Institute (formerly IMHRO), in collaboration with Janssen Research and Development, is offering three major awards for research related to brain illness and injury.

Special consideration will be given to applications that demonstrate a plan to collaborate with relevant One Mind/One Mind Institute-supported research consortia such as TRACK-TBI, NAPLS, or AURORA. Special consideration will also be given to projects that will collect data to CDISC standards, to facilitate FDA-approval of clinically validated treatments. One Mind wishes to promote rapid and open sharing of data to accelerate benefits for patients.

1. The One Mind Rising Star Trauma Translational Research Award - One grant will be offered for research toward novel therapies for brain illness with the objective to advance the translation of scientific knowledge of trauma-based disease mechanisms in neuropsychiatric illness toward benefits to patients and the healthcare system. Specifically, the program will support translational research on innovative targets, with the potential to advance discovery of therapeutic approaches in the near term. The emphasis will be on approaches that provide a viable path toward renormalizing or compensating for biological consequences of trauma (physical or emotional), either newly discovered or already known. This award is not specifically focused to advance the understanding of the fundamental mechanisms of brain diseases. One Mind is pleased to offer access to data from the 2,000-patient-cohort TRACK-TBI study for hypothesis generation or retrospective analysis.
2. The One Mind Rising Star Early Diagnostics Basic Research Award - One grant will be offered for research emphasizing innovative strategies and technologies toward the discovery and/or validation of biomarkers to predict risk for, or diagnose the onset of, severe behavioral illness, either neuropsychiatric or substance-use-based. These biomarkers may arise from processes that are either endogenous, microbiomic, related to the biological consequences of trauma (physical or emotional), or newly discovered.
3. The One Mind / Janssen Rising Star Translational Research Award - One grant will be offered for research toward novel therapies for psychiatric illness with the objective to advance the translation of scientific knowledge of underlying disease mechanisms in bipolar disorder, schizophrenia, and major depression toward benefits to patients and the healthcare system. Specifically, the program supports translational research on innovative targets, with the potential to advance discovery of therapeutic approaches in the near term. The emphasis will be on the approaches that provide a viable path toward renormalizing or compensating for novel biological alterations or those that have already been discovered. This award is not specifically focused to advance the understanding of the fundamental mechanisms of psychiatric diseases.

Award Amount: \$250,000 paid over 3 years

Indirect Costs: None

Application Deadline: Jul 15, 2017

Website: <https://www.onemindinstitute.org/research-education/rising-star-awards>

9. Clinical Surgery Fellowship, Oral and Maxillofacial Surgery Foundation (OMSF)

Education has always been an integral part of the Foundation's mission. Fellowships support post-residency training for promising oral and maxillofacial surgeons pursuing a career in academic oral and maxillofacial surgery. The purpose of the fellowship is to (a) provide to promising oral and maxillofacial surgery faculty members the opportunity to develop specialized surgical skills and to broaden their knowledge, experience and judgment in diverse areas of oral and maxillofacial surgical practice; (b) encourage through enhanced residency training and continuing education the timely and disciplined development and introduction of new and innovative surgical techniques and technologies to the membership of American Association of Oral & Maxillofacial Surgeons (AAOMS); (c) strengthen the relationship between the AAOMS membership and surgical units offering specialized and unique capabilities; and (d) assist Sponsoring Institutions while they are securing internal or other external sources of funding.

Internal Coordination: An Institution may conduct only one OMS Foundation funded Fellowship during any twelve-month award period. Sponsoring Institutions are eligible for Fellowship grants for three (3) consecutive years but are ineligible for the three (3) subsequent years.

Award Amount: \$70,000 for 1 year

Indirect Costs: None

Application Deadline: Jul 15, 2017

Website: <http://omsfoundation.org/research-education/apply/>

10. Research Support Grants, Oral and Maxillofacial Surgery Foundation (OMSF)

The purpose of the grants is to (a) further the development of scientific investigators who are committed to problems related to oral and maxillofacial surgery; and (b) encourage promising lines of research and clinical investigation consistent with the research priorities established by the specialty.

Award Amount: \$75,000 for 1 year

Indirect Costs: None

Application Deadline: Jul 15, 2017

Website: <http://omsfoundation.org/research-education/apply/>

11. Improving Pediatric ADHD Care - Innovative Implementation of a National Guideline, Pfizer, Inc. New

The American Academy of Pediatrics (AAP) and Pfizer are collaborating to offer a new grant opportunity focused on improving care for children with Attention Deficit Hyperactivity Disorder (ADHD). Selected grantees will be awarded funding to test innovative strategies to improve care based on the AAP's Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of ADHD in Children and Adolescents (AAP ADHD guideline).

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

The mission of the AAP is to attain optimal physical, mental, and social health and well-being for all infants, children, adolescents and young adults. ADHD is the most common childhood neurobehavioral disorder, affecting 11% of all children aged 4-17 in the United States. The disorder can continue into adolescence and adulthood, causing prolonged academic, conduct, social and mental health problems.

Clinical Area: Pediatric Attention Deficit Hyperactivity Disorder (ADHD)

Specific Area of Interest: It is the AAP's and Pfizer's intent to support organizations focused on designing, implementing and evaluating innovative programs that work to improve the quality of pediatric ADHD care in a primary care setting. Grantees should implement their proposed quality improvement programs in a defined population of clinician participants.

The purpose of this RFP is to encourage AAP chapters and/or other types of healthcare-focused organizations (refer to Applicant Eligibility Criteria on page 3) to build upon the pilot findings and test innovative strategies for improving the quality of ADHD care based on the AAP ADHD guideline. Grantees should implement their proposed quality improvement programs in a defined population of clinician participants. Grantees will also be expected to participate in a grantee learning community to accelerate learning and change.

This RFP is being issued by both the AAP and Pfizer. The AAP is the lead organization for review and evaluation of applications. A review committee, led by the AAP, will make decisions regarding which proposals receive funding. Grant funding will be provided by Pfizer.

Geographic Scope: United States Only

Clinical Area: Pediatric Attention Deficit Hyperactivity Disorder (ADHD)

Target Audience: Providers/teams who provide care for children in a primary care setting. The requesting organization is responsible for recruiting providers/care teams to participate.

Specific Area of Interest for this RFP:

It is the AAP's and Pfizer's intent to support organizations focusing on designing, implementing and evaluating innovative programs that work to improve the quality of pediatric ADHD care in a primary care setting. Grantees should implement their proposed quality improvement programs in a defined population of clinician participants.

Required Elements

The proposed program must include all the following:

1. Focus on implementation of one or more of the six recommendations set forth in the American Academy of Pediatrics' Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of ADHD in Children and Adolescents.
2. Use of scientific quality improvement principles and methods.
 - e.g., Lean, Lean Six Sigma, Model for Improvement, etc.
3. Provision of clinical education for participating clinicians.
 - The curriculum developed and tested during phase 1 of the CQN ADHD pilot project will be made available to grantees for use and/or adaptation.
4. A proposed set of metrics to be collected regularly throughout the project for improvement purposes and a detailed data collection plan.
 - The metrics should be tailored to the individual project and the specific data collection capabilities of the grantee, but should also align with the recommendations set forth in the AAP ADHD guideline.
 - The data collection plan must specify a data collection system and the data collection timeframe.
 - * Data collection should last at least 9 months.
 - * Grantees should make every effort to begin data collection at the start of the 2017-2018 school year (August/September 2017).
 - * Data collection must occur on at least a monthly basis. Grantees will be required to share aggregated, de-identified data with the AAP leadership team and other grantees on a monthly basis.
 - * The data collection plan should address how the grantee will collect "just-in-time" data for ongoing tests of change in the clinical environment (daily or weekly data). Grantees will not be required to share data with the AAP or other grantees on a daily or weekly basis.
 - Grantees should collect one cycle of baseline data for proposed metrics.
 - Measurement of patient outcomes is encouraged, if feasible.

If any requirement under #2, #3 or #4 is not applicable to the proposed project, the applicant should include in an explanation and/or supporting data regarding why the proposal does not adhere to these requirements.

It is not the AAP's and Pfizer's intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Award Amount: \$150,000

Indirect Costs: 28%

LOI Deadline: May 26, 2017

Website: <http://www.pfizer.com/purpose/medical-grants/request-proposals>